SEC filing · 8-K

Harrow, Inc.: Acquisition or sale completed

Harrow completed its acquisition of worldwide rights to the dry eye nasal spray TYRVAYA from Viatris, excluding Japan.

Filed October 5, 2026

Positive for the company

What happened

On October 1, 2026, Harrow closed the acquisition of TYRVAYA from Viatris Inc.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Harrow, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.